January 3, 2023 -- Children and adolescents who received a COVID-19 vaccination following multisystem inflammatory syndrome (MIS-C) reported no serious complications, including myocarditis or reoccurrence of MIS-C. The NIH-funded observational study, published January 3 in the journal JAMA Network Open, indicates that it is safe to get a vaccine after having had MIS-C.
The study helps resolve questions about whether the COVID-19 vaccine increases the risk of health problems in young people who have had MIS-C, a rare and potentially fatal immune reaction that can occur following SARS-CoV-2 infection. Data on this topic had been lacking.
MIS-C affects one in about 3,500 children and adolescents who have had COVID-19. Symptoms occur a few weeks after infection, and can range from stomach pain, fever, and rashes to heart muscle inflammation -- a serious condition called myocarditis. MIS-C's exact causes are unknown. To date, more than 9,000 U.S. patients have been diagnosed with MIS-C and 74 have died, according to data from the Centers for Disease Control and Prevention (CDC). Other studies indicate that MIS-C may be declining.
The cross-sectional study included 22 medical centers (21 in the U.S. and one in Canada). It enrolled 385 patients 5 years of age or older with prior MIS-C who were eligible for COVID-19 vaccination. Their median age was 12.2 years and 73.5% were male. The participants were racially diverse: 24.3% were Black, 31.9% were Hispanic, and 28.6% were white. Of this group, 185 (48.1%) received at least one subsequent vaccine dose. The median length of time from their MIS-C diagnosis to their first vaccine dose was nine months.
About half of the participants -- a rate similar to that of the general population -- experienced typical mild reactions, including arm soreness and fatigue, following their COVID-19 vaccination. There were no reports of serious complications such as myocarditis or MIS-C recurrence. The findings support CDC recommendations that it is safe for patients with a history of MIS-C to receive a COVID-19 vaccine at least 90 days after diagnosis.
While many patients with MIS-C make a full clinical recovery, some studies suggest chronic symptoms may linger, pointing to the need for long-term outcome studies. The current study is part of a collaborative NIH research effort which seeks to better understand how COVID-19 affects children, who account for roughly 13% of total COVID-19 cases in the U.S.
"We are very reassured by the results and this safety data should be comforting to families and healthcare professionals when considering and recommending vaccination," said co-author Dr. Matthew D. Elias, pediatric cardiologist at the Children's Hospital of Philadelphia, in a statement.
Copyright © 2023 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
